Physician profile
Hari D Kannan
NPI 1447222906
$913,392.58
in general payments reported to CMS, 2019-2025
8 companies · $170K in 2025
The $170K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161K · 2020: $74K · 2021: $125K · 2022: $79K · 2023: $195K · 2024: $109K · 2025: $170K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $167K · Travel and Lodging: $135K · Honoraria: $106K · Consulting Fee: $55K · Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $167,235.00 |
| Travel and Lodging | $135,456.67 |
| Honoraria | $106,400.00 |
| Consulting Fee | $54,937.50 |
| Food and Beverage | $10,304.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $417,407.00 | 2021-2025 | |
| Axsome Therapeutics, INC. | $229,730.96 | 2023-2025 | Auvelity |
| Allergan, INC. | $161,700.89 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $100,851.39 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $3,257.37 | 2025 | Fanapt |
| Jazz Pharmaceuticals INC. | $390.64 | 2019 | |
| Acadia Pharmaceuticals INC | $37.98 | 2019 | |
| Alfasigma USA, INC. | $16.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hari Kannan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.